| P50 | author | Adriana Rojas-Villarraga | Q54536996 |
| | Jenny Amaya-Amaya | Q60568054 |
| P2093 | author name string | Laura Montoya-Sánchez | |
| P2860 | cites work | Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants | Q24273409 |
| | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| | Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases | Q27008359 |
| | Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies | Q28169119 |
| | Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? | Q28191540 |
| | Relative risk of cardiovascular events in patients with rheumatoid arthritis | Q28192599 |
| | Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway | Q28196567 |
| | Cardiac manifestations in antiphospholipid syndrome | Q28211851 |
| | Lupus Atherosclerosis Prevention Study (LAPS) | Q82991610 |
| | Angiographically proven coronary artery disease in scleroderma | Q83136221 |
| | Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase | Q83136805 |
| | Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors | Q83164443 |
| | Atherosclerosis development in SLE patients is not determined by monocytes ability to bind/endocytose Ox-LDL | Q83199158 |
| | Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis | Q83205796 |
| | Outcomes of nonstenting percutaneous coronary intervention in patients with rheumatoid arthritis | Q83294635 |
| | Interaction between smoking and polymorphism in the promoter region of the VEGFA gene is associated with ischemic heart disease and myocardial infarction in rheumatoid arthritis | Q83506210 |
| | Impaired brachial artery flow-mediated dilation and increased carotid intima-media thickness in rheumatoid arthritis patients | Q83850095 |
| | Comorbidities in patients with primary Sjogren's syndrome: a registry-based case-control study | Q83975482 |
| | Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition | Q84021512 |
| | Hypothyroidism in rheumatoid arthritis--to screen or not to screen? | Q84052758 |
| | SLICC/ACR damage index independently associated with left ventricular diastolic dysfunction in patients with systemic lupus erythematosus | Q84066512 |
| | High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus | Q84189508 |
| | Cardiovascular risk assessment and treatment in systemic lupus erythematosus | Q84206184 |
| | Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users | Q84314761 |
| | Atherogenesis in rheumatoid arthritis: the "rheumatoid vasculopathy"? | Q84477351 |
| | Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity | Q84529188 |
| | Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study | Q84745284 |
| | Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome | Q84830607 |
| | Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis | Q84874255 |
| | [Extra-articular manifestations of rheumatoid arthritis] | Q84897597 |
| | [Relationship of silent myocardial ischiemia with the course of rheumatoid arthritis and hyperhomocysteinemia] | Q85005177 |
| | A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis | Q85239536 |
| | Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus | Q85618243 |
| | Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients | Q86358120 |
| | Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study | Q86417514 |
| | Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study | Q87400076 |
| | Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders | Q35864204 |
| | Coronary and valvular syndromes and antiphospholipid antibodies | Q35928744 |
| | Peripheral vascular disease in antiphospholipid syndrome | Q35928750 |
| | Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? | Q35953555 |
| | Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis | Q35988930 |
| | Redefining overweight and obesity in rheumatoid arthritis patients. | Q36013923 |
| | Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 |
| | Statins: immunomodulators for autoimmune rheumatic disease? | Q36088044 |
| | Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy | Q36151574 |
| | Genetic markers of cardiovascular disease in rheumatoid arthritis. | Q36165202 |
| | Atherosclerosis in patients with autoimmune disorders | Q36173656 |
| | High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis | Q36183213 |
| | Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals | Q36238859 |
| | Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study | Q36245756 |
| | Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study | Q36245829 |
| | The genetics of lupus: a functional perspective | Q36245989 |
| | Cardiac involvement in the antiphospholipid syndrome | Q36283448 |
| | Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis | Q36283486 |
| | Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies | Q36300623 |
| | Defects in regulation of local immune responses resulting in atherosclerosis | Q36316255 |
| | Accelerated atherosclerosis in autoimmune rheumatic diseases | Q36318870 |
| | Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis | Q36326701 |
| | Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms | Q36375684 |
| | Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases | Q36399112 |
| | Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis. | Q36456316 |
| | Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation | Q36465464 |
| | Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis | Q36511541 |
| | Mechanisms of disease: atherosclerosis in autoimmune diseases | Q36577423 |
| | Primary myocardial involvement in systemic sclerosis | Q36596341 |
| | Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis | Q36600485 |
| | Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus | Q36606667 |
| | Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors | Q36670021 |
| | Cardiovascular risk factors, fitness and physical activity in rheumatic diseases | Q36728516 |
| | Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis | Q39991479 |
| | Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking | Q40037298 |
| | Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis | Q40065488 |
| | Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients | Q40297850 |
| | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. | Q40461525 |
| | Massive Lower Extremity Arterial Thrombosis and Acute Hepatic Insufficiency in a Young Adult with Premature Atherosclerosis Associated with Hyperlipoprotein(a)emia and Antiphospholipid Syndrome | Q40474895 |
| | The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". | Q40541271 |
| | Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression | Q40957024 |
| | Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 |
| | Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events | Q41911950 |
| | Incidence of metabolic syndrome in systemic lupus erythematosus and its influence by glucocorticoids | Q41928456 |
| | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 |
| | Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients | Q41935758 |
| | Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients | Q41936333 |
| | The autoimmune tautology: from polyautoimmunity and familial autoimmunity to the autoimmune genes | Q42150403 |
| | Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis | Q42165744 |
| | HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis | Q42610707 |
| | Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis. | Q42651242 |
| | Subclinical atherosclerosis in scleroderma patients | Q43061735 |
| | Functional impairment of the arterial wall in primary Sjögren's syndrome: combined action of immunologic and inflammatory factors | Q43146598 |
| | Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics | Q43179448 |
| | Noncalcified coronary plaque in systemic lupus erythematosus | Q43181476 |
| | Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target. | Q43228758 |
| | Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. | Q43275139 |
| | Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 |
| | Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study | Q43474365 |
| | Impact of cardiovascular illness on hospitalization costs in patients with rheumatoid arthritis | Q43498266 |
| | Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. | Q43587941 |
| | Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis | Q43622165 |
| | Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies | Q43625524 |
| | Systemic sclerosis and risk of ischaemic stroke: a nationwide cohort study | Q43669091 |
| | The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 |
| | Risk factors for cardiovascular disease in systemic lupus erythematosus | Q43767819 |
| | Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study. | Q43810525 |
| | Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | Q43837381 |
| | Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy | Q43874803 |
| | Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study | Q43885994 |
| | Cardiovascular risk factors in Chilean patients with rheumatoid arthritis. | Q44103547 |
| | Is the heart affected in primary Sjögren's syndrome? An echocardiographic study | Q44142971 |
| | Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status | Q44264832 |
| | Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy | Q44411027 |
| | Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis | Q44453472 |
| | Glutathione S-transferase M1, T1, and P1 gene polymorphisms and carotid atherosclerosis in Korean patients with rheumatoid arthritis | Q44524615 |
| | Rate, pattern and factors related to damage in Brazilian systemic lupus erythematosus patients. | Q44641124 |
| | Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study | Q44672345 |
| | Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset | Q44729726 |
| | Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome | Q44734227 |
| | Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. | Q44738419 |
| | A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls | Q44768065 |
| | Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 |
| | Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage | Q45099953 |
| | Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. | Q45102525 |
| | Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus | Q45220914 |
| | Lipoprotein profile in limited systemic sclerosis. | Q45256816 |
| | Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis | Q45293503 |
| | Cardiovascular outcomes in male veterans with rheumatoid arthritis. | Q45331961 |
| | Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants | Q28290376 |
| | Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases | Q28744267 |
| | Inflammation, atherosclerosis, and coronary artery disease | Q29547232 |
| | The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort | Q30560762 |
| | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 |
| | Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards | Q33328447 |
| | Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography | Q33334045 |
| | Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 |
| | Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. | Q33344777 |
| | The overlap of Sjögren's syndrome with other systemic autoimmune diseases | Q33372729 |
| | Vascular disease in the antiphospholipid syndrome: A comparison with the patient population with atherosclerosis | Q33374176 |
| | Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome--a case-series | Q33375778 |
| | C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis | Q33375902 |
| | Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. | Q33379277 |
| | Anticardiolipin antibodies in systemic lupus erythematosus: prevalence and clinical associations | Q33379425 |
| | Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study | Q33387473 |
| | Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome | Q33403846 |
| | Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort | Q33448450 |
| | EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 |
| | Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX) | Q33511924 |
| | Innate and adaptive immunity in atherosclerosis | Q33659705 |
| | Mortality trends in rheumatoid arthritis: the role of rheumatoid factor | Q33709660 |
| | Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? | Q33868702 |
| | Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort | Q33871715 |
| | A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. | Q33923484 |
| | Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 |
| | Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study | Q34017775 |
| | Increased prevalence of diastolic dysfunction in rheumatoid arthritis. | Q34061175 |
| | Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2 | Q34084599 |
| | The aged cardiovascular risk patient | Q34091463 |
| | Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 |
| | The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases | Q34129198 |
| | Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus | Q34158891 |
| | Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 |
| | Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome | Q35552883 |
| | Detection of early impairment of coronary flow reserve in patients with systemic sclerosis | Q35553128 |
| | Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. | Q35554016 |
| | Primary Sjögren's syndrome: new clinical and therapeutic concepts | Q35555323 |
| | Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease | Q35557952 |
| | Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 |
| | Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients | Q35617635 |
| | Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study | Q35617716 |
| | Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis | Q35638369 |
| | Autoimmune and inflammatory mechanisms in atherosclerosis | Q35698466 |
| | 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus | Q35762542 |
| | Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis | Q35777047 |
| | Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice | Q35782654 |
| | Introducing polyautoimmunity: secondary autoimmune diseases no longer exist | Q35791637 |
| | Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles | Q35832305 |
| | Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study | Q35840758 |
| | Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. | Q51370598 |
| | Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. | Q51377213 |
| | Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. | Q51464078 |
| | Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. | Q51501693 |
| | Assessment of nutritional status and physical activity in systemic lupus erythematosus patients. | Q51515934 |
| | Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study. | Q51549596 |
| | Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. | Q51577475 |
| | Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. | Q51601971 |
| | Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. | Q51750817 |
| | Household work disability of Arab housewives with rheumatoid arthritis. | Q51767587 |
| | Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. | Q51773790 |
| | Coronary angiographic findings in asymptomatic systemic sclerosis. | Q51821801 |
| | QT-interval parameters are increased in systemic lupus erythematosus patients. | Q51831332 |
| | Microvascular involvement in systemic sclerosis: capillaroscopic findings. | Q52543221 |
| | Endothelial dysfunction in primary Sjögren syndrome. | Q52643266 |
| | Autoantibodies and biomarkers of endothelial cell activation in atherosclerosis. | Q53062627 |
| | Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999-2008 | Q53115278 |
| | A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. | Q53121954 |
| | Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients | Q53165981 |
| | Systemic lupus erythematosus risk factors for coronary artery calcifications. | Q53194239 |
| | Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. | Q53270426 |
| | Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. | Q53544079 |
| | Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. | Q53600925 |
| | The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology | Q56452307 |
| | Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients | Q56907410 |
| | Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome | Q57219336 |
| | NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis | Q57307062 |
| | TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis | Q57307074 |
| | Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis | Q57307089 |
| | The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease | Q57307093 |
| | Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors | Q57307113 |
| | High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors | Q57307115 |
| | Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes | Q57819644 |
| | Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Q58197651 |
| | HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis | Q61971712 |
| | Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis | Q61974570 |
| | Precocious intima-media thickening in patients with primary Sjögren's syndrome | Q62395171 |
| | Genetically Determined Serum Levels of Mannose-Binding Lectin Correlate Negatively with Common Carotid Intima-Media Thickness in Systemic Lupus Erythematosus | Q63728031 |
| | Mortality and Predictors of Mortality in Rheumatoid Arthritis — A Role for Mannose-binding Lectin? | Q63728035 |
| | Double role of mannose-binding lectin in relation to carotid intima–media thickness in patients with rheumatoid arthritis | Q63728039 |
| | Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis | Q63728063 |
| | Is small artery elasticity decreased prior to intima-media thickening in patients with longstanding rheumatoid arthritis? | Q64890214 |
| | Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. | Q64930193 |
| | Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 |
| | Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors | Q36757042 |
| | Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus | Q36806527 |
| | Genetic risk factors for thrombosis in systemic lupus erythematosus | Q36807470 |
| | The role of preventive cardiology in systemic lupus erythematosus | Q36821493 |
| | Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus | Q36934234 |
| | Vascular complications of scleroderma | Q36940162 |
| | Systemic antiphospholipid syndrome and atherosclerosis | Q36960925 |
| | Insights into atherosclerosis therapy in antiphospholipid syndrome | Q36984674 |
| | Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages | Q37008144 |
| | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention | Q37033345 |
| | Macrovascular disease and atherosclerosis in SSc. | Q37102816 |
| | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study | Q37141852 |
| | Hypertension in rheumatoid arthritis. | Q37158219 |
| | The autoimmune origin of atherosclerosis | Q37202020 |
| | The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus | Q37206876 |
| | Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study | Q37206912 |
| | Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis | Q37260891 |
| | Macrovascular disease in systemic sclerosis: the tip of an iceberg? | Q37265796 |
| | Mechanisms of vascular damage in SSc--implications for vascular treatment strategies | Q37265800 |
| | Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies | Q37306418 |
| | Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings | Q37319989 |
| | Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. | Q37330468 |
| | Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway | Q37349421 |
| | Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus | Q37367326 |
| | Metabolic syndrome in rheumatological diseases. | Q37377015 |
| | Autoimmunity and heart diseases: pathogenesis and diagnostic criteria | Q37427500 |
| | Cardiac complications of systemic sclerosis | Q37504315 |
| | Impact of ovarian function on cardiovascular health in women: focus on hypertension | Q37538095 |
| | SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis | Q37691093 |
| | Cardiovascular events in patients with antiphospholipid antibodies: strategies of prevention | Q37691887 |
| | Targeting IL-17 and Th17 cells in rheumatoid arthritis | Q37761422 |
| | Rheumatoid cachexia and cardiovascular disease. | Q37774545 |
| | Cardiac involvement in systemic rheumatic diseases: An update | Q37778555 |
| | Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropatic | Q45473814 |
| | Adult heart block is associated with disease activity in primary Sjögren's syndrome | Q45887768 |
| | High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. | Q45970948 |
| | The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. | Q45980690 |
| | Excess weight and associated risk factors in patients with systemic lupus erythematosus. | Q45983994 |
| | Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis | Q46100250 |
| | Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. | Q46251444 |
| | Predictors of carotid atherosclerosis in systemic lupus erythematosus. | Q46315593 |
| | High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus | Q46318778 |
| | Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study | Q46370506 |
| | Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis | Q46505203 |
| | Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. | Q46506708 |
| | Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. | Q46610997 |
| | Lipoprotein[a] and the lipid profile in patients with systemic sclerosis | Q46659733 |
| | Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus | Q46662161 |
| | Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus | Q46724748 |
| | Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease | Q46745537 |
| | Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting. | Q46771777 |
| | Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. | Q46852341 |
| | Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide | Q46859901 |
| | Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. | Q46932374 |
| | Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events | Q46968374 |
| | Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction | Q47273525 |
| | Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy | Q47389819 |
| | Antibodies against oxidized low-density lipoproteins in systemic sclerosis | Q47579190 |
| | Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy | Q47688900 |
| | Single measurements of C-reactive protein and disease activity scores are not predictors of carotid atherosclerosis in rheumatoid arthritis patients. | Q47779221 |
| | Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. | Q47967636 |
| | Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus | Q48312290 |
| | Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study | Q48409597 |
| | Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis | Q48502988 |
| | Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis | Q48949308 |
| | The relationship between carotid intima-media thickness and the activity of rheumatoid arthritis. | Q49023148 |
| | Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients | Q49209737 |
| | Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. | Q50196335 |
| | The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. | Q50417164 |
| | Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort | Q34184151 |
| | Atherosclerosis and autoimmunity | Q34243799 |
| | Vascular disease in systemic sclerosis | Q34244970 |
| | HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab | Q34270268 |
| | Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis | Q34271982 |
| | Coronary artery disease in systemic lupus erythematosus: A review of the literature | Q34280725 |
| | Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 |
| | Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden | Q34307622 |
| | Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies | Q34320519 |
| | Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure | Q34322056 |
| | The global burden of chronic diseases: overcoming impediments to prevention and control | Q34323994 |
| | Clinical manifestations and early diagnosis of Sjögren syndrome | Q34330087 |
| | Antiphospholipid syndrome; its implication in cardiovascular diseases: a review | Q34331685 |
| | The pathogenesis of the antiphospholipid syndrome | Q34332601 |
| | Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus | Q34338929 |
| | Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus | Q34343906 |
| | Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis | Q34401259 |
| | Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 |
| | Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. | Q34482096 |
| | Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america | Q34495257 |
| | Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis | Q34515105 |
| | Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study | Q34624148 |
| | Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 |
| | Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 |
| | Dyslipidaemia in rheumatological autoimmune diseases | Q35029916 |
| | Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis | Q35082399 |
| | 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort | Q35086343 |
| | High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids | Q35138355 |
| | Atherosclerosis and antiphospholipid syndrome | Q35148621 |
| | Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions | Q35214718 |
| | Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis | Q35511202 |
| | Macrovascular disease and systemic sclerosis | Q35548842 |
| | Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus | Q35552164 |
| | Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study | Q35552242 |
| | Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective Study | Q37789100 |
| | Atherosclerosis and macrovascular involvement in systemic sclerosis: Myth or reality | Q37791682 |
| | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 |
| | Hydroxychloroquine: from malaria to autoimmunity | Q37827403 |
| | Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment | Q37833721 |
| | Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action | Q37859226 |
| | Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center | Q37866668 |
| | The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk | Q37871668 |
| | Rheumatoid arthritis and metabolic syndrome. | Q37882443 |
| | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. | Q37883018 |
| | Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis | Q37896358 |
| | Vascular function and morphology in rheumatoid arthritis: a systematic review | Q37934239 |
| | Menopause in patients with autoimmune diseases | Q37961466 |
| | Immunomodulation at epithelial sites by obesity and metabolic disease | Q37967444 |
| | Risk factors for cardiovascular disease in rheumatoid arthritis | Q37976283 |
| | To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer | Q37976421 |
| | Heart involvement in rheumatoid arthritis: systematic review and meta-analysis | Q38019111 |
| | The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review | Q38082909 |
| | Novel risk factors for cardiovascular disease in rheumatoid arthritis | Q38098935 |
| | Review: evidence that systemic sclerosis is a vascular disease | Q38105984 |
| | Rheumatoid arthritis and cardiovascular disease | Q38149252 |
| | The diagnosis and clinical significance of polyautoimmunity | Q38178462 |
| | Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? | Q38185646 |
| | Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. | Q38190247 |
| | The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 |
| | Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis | Q38465160 |
| | Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. | Q38479125 |
| | Serum oxidized low-density lipoproteins in rheumatoid arthritis | Q38518891 |
| | The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. | Q39400939 |
| | Shortened telomere length in patients with systemic lupus erythematosus | Q39468931 |
| | Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness | Q39550704 |
| | Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus | Q39641926 |
| | Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon | Q39799956 |
| | TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. | Q50850816 |
| | Metabolic syndrome in Chinese patients with systemic lupus erythematosus: no association with plasma cortisol level. | Q50861922 |
| | Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. | Q50957777 |
| | Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. | Q51202425 |
| | Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. | Q51332462 |
| | TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. | Q51354485 |
| | Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. | Q51364734 |
| | Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 |
| | The impact of rheumatoid arthritis on the homemaker | Q69172571 |
| | Arterial hypertension in systemic lupus erythematosus | Q71222544 |
| | Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis | Q71935209 |
| | Systemic lupus erythematosus in São Paulo/Brazil: a clinical and laboratory overview | Q72345758 |
| | Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | Q72369034 |
| | Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis | Q72650138 |
| | Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 |
| | Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit | Q73854778 |
| | Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease | Q74006768 |
| | Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators | Q74302912 |
| | Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration | Q74527172 |
| | Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients | Q77391585 |
| | Antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome | Q79241434 |
| | Traditional cardiovascular risk factors in primary Sjögren's syndrome--role of dyslipidaemia | Q79249625 |
| | Is systemic lupus erithematosus a new risk factor for atherosclerosis? | Q79290805 |
| | Acceleration of atherosclerosis during the course of rheumatoid arthritis | Q79348208 |
| | Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease | Q79354392 |
| | [Follow-up studies of rheumatoid arthritis patients with the presence of antiphospholipid antibodies] | Q79461654 |
| | Immunization of LDL receptor-deficient mice with beta2-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques | Q79478659 |
| | Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications | Q79631405 |
| | Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis | Q79691193 |
| | Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis | Q79698753 |
| | Atherosclerosis and autoimmunity | Q79791340 |
| | High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression | Q79796742 |
| | Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab | Q79996729 |
| | Antirheumatic drug use and the risk of acute myocardial infarction | Q80016233 |
| | Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study | Q80038470 |
| | Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies | Q80171473 |
| | [Hyperhomocystinemia as a thrombotic risk factor in patients suffering from systemic lupus erithematosus and antiphospholipid syndrome] | Q80261931 |
| | Antiphospholipid antibodies in acute coronary syndrome | Q80434476 |
| | Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis | Q80442338 |
| | Associations between left ventricular myocardial involvement and endothelial dysfunction in systemic sclerosis: noninvasive assessment in asymptomatic patients | Q80511391 |
| | Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis | Q80573645 |
| | Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis | Q80808131 |
| | Rheumatoid arthritis, periodontal disease and coronary artery disease | Q80975481 |
| | Incidence of thromboembolic events in patients with primary Sjögren's syndrome | Q81093887 |
| | OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement | Q81125970 |
| | Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis | Q81290300 |
| | Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis | Q81349086 |
| | Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis | Q81349091 |
| | Prediction of mortality in rheumatoid arthritis based on disease activity markers | Q81463187 |
| | Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 |
| | Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations | Q81597280 |
| | Premature atherosclerosis in systemic lupus erythematosus | Q81794167 |
| | Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis | Q82299864 |
| | Serum pentraxin 3 and interleukin-6 are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis | Q82345990 |
| | The major determinants of arterial stiffness in Korean patients with rheumatoid arthritis are age and systolic blood pressure, not disease-related factors | Q82367271 |
| | Endothelial dysfunction in systemic lupus erythematosus: evaluation with 13N-ammonia PET | Q82460722 |
| | Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy | Q82734935 |
| | [Ventricular diastolic dysfunction in rheumatoid arthritis] | Q82786404 |
| | Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model | Q82835412 |
| | Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients | Q82852725 |
| | Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis | Q82868229 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| | rheumatism | Q684924 |
| | systemic scleroderma | Q5340515 |
| | autoimmune disease | Q8084905 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 367359 | |
| P577 | publication date | 2014-07-22 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Cardiovascular involvement in autoimmune diseases | |
| P478 | volume | 2014 | |